Endocrine Abstracts

Alemtuzumab is a monoclonal antibody directed against CD52 licenced for the treatment of relapsing remitting multiple sclerosis (MS). Thyroid dysfunction occurs in one third of patients, likely secondary to lymphocyte reconstitution.Case 1: A 36 year old female, treated with alemtuzumab 15 months prior, presented to antenatal clinic at 12 weeks gestation with symptoms of thyrotoxicosis. fT4 was 83.7 pmol/l (RR 12-22), TSH suppressed, TRAB positive. She w...